Ad is loading...
PRME
Price
$2.97
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
XOMA
Price
$30.20
Change
+$0.13 (+0.43%)
Updated
Nov 22 closing price
103 days until earnings call
Ad is loading...

PRME vs XOMA

Header iconPRME vs XOMA Comparison
Open Charts PRME vs XOMABanner chart's image
Prime Medicine
Price$2.97
Change-$0.00 (-0.00%)
Volume$991.87K
CapitalizationN/A
XOMA Royalty
Price$30.20
Change+$0.13 (+0.43%)
Volume$40.01K
CapitalizationN/A
PRME vs XOMA Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
PRME vs. XOMA commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Sell and XOMA is a Sell.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (PRME: $3.20 vs. XOMA: $30.20)
Brand notoriety: PRME and XOMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 81% vs. XOMA: 152%
Market capitalization -- PRME: $419.71M vs. XOMA: $355.84M
PRME [@Biotechnology] is valued at $419.71M. XOMA’s [@Biotechnology] market capitalization is $355.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.6B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileXOMA’s FA Score has 1 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • XOMA’s FA Score: 1 green, 4 red.
According to our system of comparison, XOMA is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while XOMA’s TA Score has 3 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 5 bearish.
  • XOMA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both PRME and XOMA are a bad buy in the short-term.

Price Growth

PRME (@Biotechnology) experienced а -4.33% price change this week, while XOMA (@Biotechnology) price change was -0.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

PRME is expected to report earnings on Nov 13, 2024.

XOMA is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($420M) has a higher market cap than XOMA($356M). XOMA YTD gains are higher at: 66.804 vs. PRME (-63.883). XOMA has higher annual earnings (EBITDA): -18.71M vs. PRME (-207.13M). PRME has more cash in the bank: 176M vs. XOMA (143M). PRME has less debt than XOMA: PRME (41.2M) vs XOMA (119M). XOMA has higher revenues than PRME: XOMA (9.71M) vs PRME (800K).
PRMEXOMAPRME / XOMA
Capitalization420M356M118%
EBITDA-207.13M-18.71M1,107%
Gain YTD-63.88366.804-96%
P/E RatioN/AN/A-
Revenue800K9.71M8%
Total Cash176M143M123%
Total Debt41.2M119M35%
FUNDAMENTALS RATINGS
PRME vs XOMA: Fundamental Ratings
PRME
XOMA
OUTLOOK RATING
1..100
5720
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
1
Undervalued
PROFIT vs RISK RATING
1..100
10064
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
9441
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XOMA's Valuation (1) in the Biotechnology industry is significantly better than the same rating for PRME (73) in the null industry. This means that XOMA’s stock grew significantly faster than PRME’s over the last 12 months.

XOMA's Profit vs Risk Rating (64) in the Biotechnology industry is somewhat better than the same rating for PRME (100) in the null industry. This means that XOMA’s stock grew somewhat faster than PRME’s over the last 12 months.

XOMA's SMR Rating (97) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that XOMA’s stock grew similarly to PRME’s over the last 12 months.

XOMA's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for PRME (94) in the null industry. This means that XOMA’s stock grew somewhat faster than PRME’s over the last 12 months.

XOMA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that XOMA’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMEXOMA
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
N/A
Bullish Trend 1 day ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
73%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBRNX86.550.46
+0.53%
Fidelity Advisor Stock Sel All Cp I
RYENX259.761.23
+0.48%
Rydex Energy A
OSTVX17.690.02
+0.11%
Osterweis Growth & Income Fund
FADAX23.870.01
+0.04%
Fidelity Advisor Dividend Growth A
ARIFX11.45N/A
N/A
Aristotle International Eq I

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+7.74%
BEAM - PRME
61%
Loosely correlated
+6.23%
NTLA - PRME
61%
Loosely correlated
+3.62%
CRSP - PRME
60%
Loosely correlated
+3.43%
ABCL - PRME
57%
Loosely correlated
+1.47%
RXRX - PRME
56%
Loosely correlated
-0.87%
More

XOMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, XOMA has been loosely correlated with LYEL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if XOMA jumps, then LYEL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMA
1D Price
Change %
XOMA100%
+0.43%
LYEL - XOMA
37%
Loosely correlated
+3.64%
PRME - XOMA
33%
Loosely correlated
+7.74%
ZNTL - XOMA
33%
Poorly correlated
+1.57%
CRSP - XOMA
32%
Poorly correlated
+3.43%
CRBU - XOMA
31%
Poorly correlated
+2.02%
More